University of Colorado and Incyte Initiate Phase 1/2 Clinical Trial of Ruxolitinib Combination Therapy for Sickle Cell Disease Patients
Clinical Trial Initiation and the Role of Ruxolitinib
The University of Colorado Denver, in collaboration with Incyte (INCY), has initiated a Phase 1/2 clinical trial (starting April 10, 2026) to evaluate ruxolitinib (brand name: Jakafi) in combination with reduced-intensity conditioning (RIC) for haploidentical hematopoietic cell transplantation (Haplo-HCT) in patients with Sickle Cell Disease (SCD). This study aims to prevent graft failure following Haplo-HCT by adding ruxolitinib, a JAK1/JAK2 inhibitor, to the RIC regimen. The trial is garnering attention from both the academic and industrial communities as it offers a new transplantation opportunity for pediatric and young adult patients who previously lacked access due to the unavailability of a matched donor.
Competitive Landscape with Existing Therapies
The SCD market is currently experiencing increased competition with the emergence of gene therapies such as Casgevy from Vertex and CRISPR Therapeutics, and Lyfgenia from bluebird bio. However, these gene therapies face limitations due to their high cost (up to $3.1 million) and complex manufacturing processes, which significantly restrict patient access. In contrast, Haplo-HCT using ruxolitinib offers a cost-effective and readily available treatment option, as it can be administered immediately using a half-matched donor, such as a parent or sibling.
Clinical Trial Design and Evaluation Metrics
This clinical trial (NCT07252050) will enroll 24 pediatric and young adult patients, with a total study duration of four years, including two years for patient recruitment and two years for post-transplant follow-up. The primary endpoints include time to neutrophil and platelet recovery, as well as event-free survival (EFS) and overall survival (OS), to comprehensively assess both safety and efficacy. Ruxolitinib has already been approved by the FDA as a treatment for graft-versus-host disease (GVHD), demonstrating a well-established safety profile, which contributes to the high expectations for the success of this clinical trial.
Market Growth and Business Outlook
The global SCD treatment market is projected to grow significantly from approximately $3.43 billion in 2025 to up to $15.81 billion by 2033. Ruxolitinib, a key product for Incyte, generated annual revenue of $3.09 billion in 2025, and is expected to reach up to $3.27 billion in 2026, making it a blockbuster drug. If this trial is successful, ruxolitinib will expand its indications to include pre-transplant conditioning and immune modulation, further strengthening its revenue growth potential.
This Phase 1/2 clinical trial is a key focus for investors and the industry, as it presents an alternative platform to address the existing high-cost gene therapies, such as Vertex's Casgevy, in the SCD treatment market, which is valued at $3.43 billion as of 2025. In the short term, it can directly contribute to expanding the donor pool for haploidentical hematopoietic cell transplantation by providing safety data for ruxolitinib, a blockbuster drug that has already surpassed $3.09 billion in annual revenue. In the medium to long term, by significantly reducing graft failure rates through improved transplant success, it will drive the overall growth potential of the hematopoietic cell transplantation market and diversify new revenue streams for established therapies. Furthermore, the lower cost and ease of implementation compared to gene editing-based therapies will provide immediate and widespread clinical adoption incentives for healthcare providers and researchers upon successful completion of the trial.
Source: ClinicalTrials.gov (api_ct)